Raymond James Financial upgraded shares of Hill-Rom (NYSE:HRC) from a market perform rating to an outperform rating in a report released on Wednesday, Marketbeat.com reports. Raymond James Financial currently has $94.00 price target on the medical technology company’s stock.
Other research analysts also recently issued research reports about the stock. ValuEngine raised shares of Hill-Rom from a hold rating to a buy rating in a research report on Thursday, November 16th. Zacks Investment Research raised shares of Hill-Rom from a hold rating to a buy rating and set a $90.00 target price on the stock in a research report on Friday, October 27th. KeyCorp reissued a buy rating and set a $82.00 target price on shares of Hill-Rom in a research report on Tuesday, October 17th. Stifel Nicolaus raised their target price on shares of Hill-Rom from $84.00 to $85.00 and gave the company a buy rating in a research report on Monday, November 6th. Finally, Needham & Company LLC cut their target price on shares of Hill-Rom from $93.00 to $90.00 and set a buy rating on the stock in a research report on Monday, November 6th. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of $90.75.
Shares of Hill-Rom (NYSE HRC) opened at $87.38 on Wednesday. Hill-Rom has a twelve month low of $55.04 and a twelve month high of $87.64. The firm has a market cap of $5,750.00, a PE ratio of 43.91, a P/E/G ratio of 1.62 and a beta of 1.19. The company has a current ratio of 1.77, a quick ratio of 1.34 and a debt-to-equity ratio of 1.55.
The firm also recently announced a quarterly dividend, which was paid on Friday, December 29th. Shareholders of record on Friday, December 15th were given a dividend of $0.18 per share. This represents a $0.72 dividend on an annualized basis and a yield of 0.82%. The ex-dividend date was Thursday, December 14th. Hill-Rom’s dividend payout ratio (DPR) is 36.18%.
In other news, SVP Paul Sherwood Johnson sold 1,000 shares of Hill-Rom stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $82.99, for a total value of $82,990.00. Following the transaction, the senior vice president now owns 1,066 shares of the company’s stock, valued at approximately $88,467.34. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO John J. Greisch sold 100,000 shares of Hill-Rom stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $82.82, for a total transaction of $8,282,000.00. Following the completion of the transaction, the chief executive officer now directly owns 230,851 shares in the company, valued at approximately $19,119,079.82. The disclosure for this sale can be found here. Insiders have sold a total of 226,241 shares of company stock worth $18,708,644 in the last three months. Insiders own 2.20% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. BlackRock Inc. grew its position in shares of Hill-Rom by 3.1% in the 2nd quarter. BlackRock Inc. now owns 5,226,138 shares of the medical technology company’s stock worth $416,053,000 after buying an additional 159,074 shares during the last quarter. State Street Corp grew its position in shares of Hill-Rom by 2.7% in the 2nd quarter. State Street Corp now owns 1,681,107 shares of the medical technology company’s stock worth $133,831,000 after buying an additional 43,645 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Hill-Rom by 4.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,288,471 shares of the medical technology company’s stock worth $95,348,000 after buying an additional 52,863 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of Hill-Rom by 298.1% in the 3rd quarter. Wells Fargo & Company MN now owns 1,133,900 shares of the medical technology company’s stock worth $83,908,000 after buying an additional 849,050 shares during the last quarter. Finally, Koch Industries Inc. purchased a new position in shares of Hill-Rom in the 2nd quarter worth approximately $1,007,000. 82.33% of the stock is currently owned by hedge funds and other institutional investors.
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.